Phase I Study of Bevacizumab, Everolimus, and Panobinostat (LBH-589) in Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus and panobinostat (LBH-589) when administered in combination in patients with advanced solid tumor malignancies. EXPERIMENT DESIGN: Subjects received 10 mg of panobinostat three times w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Strickler, John H., Starodub, Alexander N., Jia, Jingquan, Meadows, Kellen L., Nixon, Andrew B., Dellinger, Andrew, Morse, Michael A., Uronis, Hope E., Marcom, P. Kelly, Zafar, S. Yousuf, Haley, Sherri T., Hurwitz, Herbert I.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3793400/
https://ncbi.nlm.nih.gov/pubmed/22744359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1911-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge